Pushing weight – With Billions at risk, biotech firms lobby states to limit generics

    Insider
    (From The New York Times) In statehouses around the country, some of the nation's biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, pote…

    We are glad you enjoy reading Business Report.

    Continue reading this story and get ACCESS to all our content from any device with a subscription now.

    • Get access to more than a decade of story archives.
    • Get access to our searchable data center of TOP LISTS.
    • Get exclusive content only available to INSIDERS.